Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Deep dive on Aditxt Inc. (ADTX), a highly distressed micro-cap trying to build an ecosystem around immune tolerance, precision diagnostics and women’s health, while struggling with going concern warnings, heavy dilution and a very fragile balance sheet.
On December 16, 2025, the FDA formally extended the PDUFA target action date for reproxalap in dry eye disease from December 16, 2025 to March 16, 2026, after Aldeyra submitted the Clinical Study Report (CSR) for its dry-eye field trial to the NDA at the FDA’s request.
Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of injectable biologics designed to selectively engage and modulate disease-specific T cells using its Immuno-STAT platform, targeting both autoimmune disease and cancer.
Fortress Biotech has evolved into a hybrid model: part commercial dermatology company (via Journey Medical), part royalty/affiliate platform with exposure to multiple late-stage assets developed by partners and subsidiaries.
Rocket Pharmaceuticals is a gene therapy-focused company with disclosed programs across lentiviral (hematology) and AAV (cardiovascular) platforms, as described in SEC-filed materials.
Grace Therapeutics has disclosed that it submitted an NDA for GTx-104 (intravenous nimodipine) on June 25, 2025, and that the FDA accepted the application for review with a PDUFA target date of April 23, 2026.
This week delivered a clear “biotech reality check” mix: multiple FDA decisions (including a first-in-class gene therapy), two new oral options for gonorrhea, and several high-visibility clinical readouts across obesity/metabolic and rare disease. The flow of headlines was “event-driven”, with market attention concentrating on hard endpoints, safety/tolerability, and execution quality.
The coming week looks like a genuine pivot week for global markets, with three macro catalysts in sequence that will reshape expectations on rates, growth and inflation. The backdrop is a rotation into small caps and cyclicals, supported by a Fed that has shifted into a less aggressive “pause” mode and by a potential divergence between central banks: the BoE is expected to cut (18 Dec), the ECB is likely to stay on hold, and US CPI (18 Dec) together with labour data will refine the timing of 2026 rate cuts.
Tenax Therapeutics is advancing oral levosimendan for pulmonary hypertension associated with HFpEF (PH-HFpEF), with a registrational path built around the LEVEL Phase 3 program and a planned second global Phase 3 study (LEVEL-2) accepted by FDA in 2025.
SANA Biotechnology is often framed as a high-risk / high-reward cellular engineering story. The core thesis revolves around its proprietary hypoimmune (HIP) platform: engineered cells designed to evade immune rejection, with the long-term goal of enabling allogeneic cell therapies without chronic immunosuppression.
Viking Therapeutics is one of the most watched “metabolic” biotechs because it is trying to build a two-lane story: (1) obesity with VK2735 (the same molecule in injectable and oral tablet forms), and (2) MASH/NASH with VK2809 (thyroid receptor beta agonist with histology data).
(BCRX) Update: FDA Expands ORLADEYO Approval to Younger Children | Merlintrader trading Blog
Altimmune announced a succession plan under which Jerry Durso will assume the role of President & CEO on January 1, 2026, while outgoing CEO Vipin Garg remains an advisor through June 30, 2026.
Cytokinetics is a late-stage cardiovascular biotech whose investment case now turns almost entirely around aficamten, a next-generation cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy (oHCM). The clinical package in oHCM is strong: the pivotal SEQUOIA-HCM trial versus placebo and the active-control MAPLE-HCM trial versus metoprolol both met their primary endpoints with clinically meaningful gains in peak oxygen uptake (pVO₂), improved symptoms and a safety profile that appears manageable so far.
AC Immune’s ACI-7104.056 is an active peptide vaccine designed to raise antibodies against misfolded α-synuclein in early Parkinson’s disease (PD). The ongoing Phase 2 VacSYn trial is the first randomized, double-blind study to show that such an approach can consistently drive very high antibody titers that reach the CNS and are associated with stabilization of multiple disease-relevant biomarkers.
Denali Therapeutics is a late-stage biotech focused on neurodegenerative and lysosomal storage diseases, with a proprietary Transport Vehicle (TV) platform to move biologics across the blood–brain barrier. The investment case in the next 12–18 months is dominated by the accelerated approval decision for DNL310 (tividenofusp alfa) in Hunter syndrome (MPS II), alongside the company’s ability to fund and execute a first commercial launch while advancing a broader pipeline.
FDA PDUFA Catalyst Report January 2026 | Merlintrader trading Blog English Italiano FDA PDUFA Catalyst Report – January 2026 Report Catalysts FDA PDUFA – Gennaio 2026 Key biotech approval events with price scenarios and qualitative sentiment for active traders. Principali…
Atara Biotherapeutics is a small-cap cell therapy company whose equity story is now essentially a single binary catalyst: the U.S. FDA decision on tab-cel (tabelecleucel) for EBV-positive PTLD, with a Priority Review PDUFA action date on 10 January 2026. The company has already divested or discontinued its other programs and has transferred most tab-cel operational responsibilities to Pierre Fabre Laboratories. What remains for shareholders is a high-volatility, high-uncertainty exposure to the outcome of that regulatory event and its knock-on impact on liquidity and solvency.
Delta today looks like the carrier you used to book for demanding but pragmatic business clients. Strong hub positioning in Atlanta, a wide global network and a product built around a rich mix of premium cabins and corporate traffic.
Aldeyra Therapeutics is a clinical-stage biotech focused on inflammation, oxidative stress and ocular / metabolic diseases via its RASP platform. The lead asset, Reproxalap, is currently under FDA review for dry eye disease with a target action date of December 16, 2025 — a highly binary event coming after previous Complete Response Letters (CRLs) in 2023 and 2025.